Illumina, Inc. vs iShares TIPS Bond ETF — how do they compare? Illumina, Inc. trades at $190.85 (market cap $27.94B), while iShares TIPS Bond ETF trades at $107.85. The key difference: Illumina, Inc. is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | TIP | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Fixed Income |
52-Week High | $194.33 | $112.20 |
52-Week Low | $91.00 | $107.91 |
Enterprise Value | $29.33B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
TIP trades at $108.05, down 0.2% today, with technical indicators showing a bearish bias from moving averages but neutral oscillators. The stock lacks disclosed valuation metrics like P/E and P/S, and recent news highlights bond market volatility and Federal Reserve uncertainty influencing investor sentiment. Dividend payments are scheduled for 2026, providing income visibility.
Outlook is cautious due to bearish technical signals and macroeconomic risks from potential Fed rate hikes. Investment opportunities include dividend income, but risks involve market volatility and lack of current fundamental data. Investors should await earnings reports for clarity on financial health.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →